The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

Table 1

Basic data on study participants (𝑁=14).

Age at enrollment (yrs), mean (SD), and range	24.4 (11.8), 4.5–47.4
Gender	8 (57%) male; 6 (43%) female
Age at diagnosis (yrs), mean (SD), and range	6.8 (5.7), 2–25
Disease duration (yrs), mean (SD), and range	17.5 (12.6), 0.7–43.7
*Frequency of attacks per screening month	3.3 (1.2, 3.6), 1–4.6
*Frequency of attacks per month of rilonacept	0.8 (0.2, 1.2), 0–5
*Frequency of attacks per month of placebo	2 (0.9, 2.4), 0.5–3.1

∗Attack frequency data is shown by medians (1st and 3rd quartiles), ranges.